- Home
- TKC vs GH Comparison
TKC vs GH Comparison
Compare TKC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKC
- GH
- Stock Information
- Founded
- TKC 1993
- GH 2011
- Country
- TKC Turkey
- GH United States
- Employees
- TKC N/A
- GH N/A
- Industry
- TKC Telecommunications Equipment
- GH Medical Specialities
- Sector
- TKC Telecommunications
- GH Health Care
- Exchange
- TKC Nasdaq
- GH Nasdaq
- Market Cap
- TKC 5.2B
- GH 4.9B
- IPO Year
- TKC 2000
- GH 2018
- Fundamental
- Price
- TKC $5.78
- GH $49.14
- Analyst Decision
- TKC
- GH Strong Buy
- Analyst Count
- TKC 0
- GH 20
- Target Price
- TKC N/A
- GH $54.35
- AVG Volume (30 Days)
- TKC 953.5K
- GH 2.2M
- Earning Date
- TKC 05-09-2025
- GH 08-06-2025
- Dividend Yield
- TKC 4.14%
- GH N/A
- EPS Growth
- TKC 3.80
- GH N/A
- EPS
- TKC 0.28
- GH N/A
- Revenue
- TKC $4,535,065,308.00
- GH $773,996,000.00
- Revenue This Year
- TKC $30.06
- GH $23.14
- Revenue Next Year
- TKC $30.03
- GH $21.42
- P/E Ratio
- TKC $8.06
- GH N/A
- Revenue Growth
- TKC 2.83
- GH 28.20
- 52 Week Low
- TKC $5.66
- GH $20.14
- 52 Week High
- TKC $8.47
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- TKC 37.43
- GH 62.17
- Support Level
- TKC $5.78
- GH $48.00
- Resistance Level
- TKC $6.01
- GH $51.71
- Average True Range (ATR)
- TKC 0.10
- GH 2.67
- MACD
- TKC -0.05
- GH 0.39
- Stochastic Oscillator
- TKC 2.11
- GH 78.60
About TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.